

**Table S1.** Patient demographics of patient cohort A (Caucasians)

	<b>I/I</b>	<b>I/T</b>	<b>T/T</b>	<b>P value*</b>
<b>Number of patients</b>	2219	568	64	
<b>Continent</b>				
Europe	1882 (84.8%)	487 (85.7%)	57 (89.1%)	0.63
North America	337 (15.2%)	81 (14.3%)	7 (10.9%)	
<b>Age (years)</b>				
18–64	1999 (90.1%)	506 (89.1%)	60 (93.8%)	0.53
65+	220 ( 9.9%)	62 (10.9%)	4 ( 6.2%)	
Mean (range)	47.6 (18–76)	47.8 (18–74)	49.0 (24–69)	
<b>Gender</b>				
Male	1374 (61.9%)	353 (62.1%)	36 (56.2%)	0.64
Female	845 (38.1%)	215 (37.9%)	28 (43.8%)	
<b>Transplant year</b>				
1988 – 1997	1452 (65.4%)	373 (65.7%)	40 (62.5%)	0.87
1998 – 2010	767 (34.6%)	195 (34.3%)	24 (37.5%)	
<b>Transplant number</b>				
1	1885 (84.9%)	497 (87.5%)	51 (79.7%)	0.13
>1	334 (15.1%)	71 (12.5%)	13 (20.3%)	
<b>HLA mismatch</b>				
0 – 1	328 (14.8%)	85 (15.0%)	6 ( 9.4%)	0.72
2 – 4	1576 (71.0%)	404 (71.1%)	51 (79.7%)	
5 – 6	315 (14.2%)	79 (13.9%)	7 (10.9%)	
<b>Calcineurin inhibitors</b>				
Cyclosporine	1871 (84.3%)	490 (86.3%)	54 (84.4%)	0.53
Tacrolimus	348 (15.7%)	78 (13.7%)	10 (15.6%)	
<b>Antiproliferative</b>				
Azathioprine	1010 (45.5%)	266 (46.8%)	21 (32.8%)	0.20
Mycophenolate	701 (31.6%)	180 (31.7%)	22 (34.4%)	
None	508 (22.9%)	122 (21.5%)	21 (32.8%)	
<b>Steroids</b>				
Yes	2180 (98.2%)	560 (98.6%)	63 (98.4%)	0.89
No	39 ( 1.8%)	8 ( 1.4%)	1 ( 1.6%)	

\* Fisher test